Headlines about Leap Therapeutics (NASDAQ:LPTX) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Leap Therapeutics earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.4690423046981 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of NASDAQ LPTX opened at $7.37 on Tuesday. Leap Therapeutics has a 12 month low of $4.90 and a 12 month high of $10.25. The company has a market cap of $106.87 million, a PE ratio of -2.23 and a beta of -0.25.
Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, August 8th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.01). research analysts anticipate that Leap Therapeutics will post -2.18 earnings per share for the current fiscal year.
About Leap Therapeutics
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Recommended Story: How to Invest in Marijuana Stocks
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.